Skip to main content

Table 1 Clinical characteristics of rheumatoid arthritis patients at baseline, stratified by sex

From: Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry

 

Male (n = 742, 21.9%)

Female (n = 2642, 78.1%)

Total (n = 3384)

P

Age at diagnosis (years, mean, SD)

50.3 (12.7)

47.5 (13.3)

48.1 (13.2)

 < 0.001

Age at treatment start (years, mean, SD)

57 (11.5)

54.8 (12.6)

55.3 (12.4)

 < 0.001

RA duration at treatment start (years, mean, SD)

6.7 (7.2)

7.3 (7.5)

7.2 (7.4)

0.031

Seropositivity (n, %)

551 (74.3)

1921 (72.7)

2472 (73.1)

0.849

Cancer (n, %)

32 (4.3)

118 (4.5)

150 (4.4)

0.857

Hypercholesterolemia (n, %)

124 (16.7)

396 (15.0)

520 (15.4)

0.23

Arterial hypertension (n, %)

127 (17.1)

368 (13.9)

495 (14.6)

0.026

Diabetes (n, %)

90 (12.2)

154 (5.9)

244 (7.2)

 < 0.001

COPD (n, %)

58 (7.9)

51 (1.9)

109 (3.2)

 < 0.001

Interstitial lung disease (n, %)

61 (8.2)

71 (2.7)

132 (4.5)

 < 0.001

Osteoporosis (n, %)

27 (3.6)

312 (11.8)

339 (10.0)

 < 0.001

Peptic ulcer (n, %)

16 (0.8)

17 (1.1)

33 (1.0)

 < 0.001

Moderate-severe chronic kidney disease (n, %)

23 (3.1)

31 (1.2)

54 (1.6)

 < 0.001

Smoking habit (n, %)

Non-smoker

291 (39.2)

1759 (66.6)

2050 (60.6)

 < 0.001

 

Smoker

220 (29.7)

426 (16.1)

646 (19.1)

 
 

Former smoker

186 (25.1)

305 (11.5)

491 (14.5)

 
 

Unknown

45 (6.1)

152 (5.8)

197 (5.8)

 

Sjögren’s syndrome (n, %)

12(1.6)

159 (6.0)

171 (5.1)

 < 0.001

Charlson comorbidity index (median, IQR)

1 [1, 2]

1 [1 - 1]

1 [1 - 1]

 < 0.001

BMI (median, IQR)

27.1 [24.6—29.8]

26.1 [22.9—30.1]

26.4 [23.3—30.1]

 < 0.001

BMI (n, %)

Normal weight

190 (25.6)

912 (34.5)

1102 (32.6)

 < 0.001

 

Overweight

277 (37.3)

706 (26.7)

983 (29.1)

 
 

Obesity

148 (20.0)

563 (21.3)

711 (21.0)

 
 

Unknown

127 (17.1)

461 (17.5)

588 (17.4)

 

Concomitant treatment (n, %)

Methotrexate

421 (56.7)

1390 (52.6)

1811 (53.5)

0.046

 

Other csDMARDs*

251 (33.8)

989 (37.4)

1240 (36.6)

0.072

 

Glucocorticoids

480 (64.7)

1622 (61.4)

2102 (62.1)

0.102

Disease activity

DAS28-ESR (mean, SD)

4.4 (1.4)

4.7 (1.2)

4.6 (1.3)

 < 0.001

 

DAS28-CRP (mean, SD)

3.6 (1.2)

3.7 (1.1)

3.7 (1.1)

0.271

 

SJC (median, IQR)

3 [1–6]

3 [1–6]

3 [1–6]

0.947

 

TJC (median, IQR)

4 [2–9]

5 [2–9]

5 [2–9]

0.009

 

PGA-VAS (median, IQR)

6 [5–7]

6 [5–8]

6 [5–8]

0.006

 

ESR mm/h (median, IQR)

18 [8–36]

23 [12—39]

22 [11—38]

 < 0.001

 

CRP mg/L (median, IQR)

7.9 [3.4—19.4]

6 [2.2—14.2]

6.5 [2.5—15.2]

 < 0.001

  1. Abbreviations: SD standard deviation, IQR interquartile range, COPD Chronic Obstructive Pulmonary Disease, BMI body mass index, DAS disease activity score, TJC tender joint count, SJC swollen joint count, PGA-VAS patient global assessment visual analogue scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein
  2. *Other csDMARDs include: leflunomide, sulfasalazine, gold salts, azathioprine, hydroxychloroquine, mesalazine, cyclophosphamide and cyclosporine
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us